Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-intensity statin plus ezetimibe vs high-intensity statin in prediabetic ASCVD patients
NCT05579626Phase 4Enrolling by invitation
- Start
- Mar 2023
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ezetimibe in atherosclerotic cardiovascular disease (ASCVD). Started Mar 2023; status: enrolling by invitation.
02
Drugs
ezetimibe
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT05579626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579626.